![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EDAP Receives FDA Clearance of its Ablatherm-Fusion Device
EDAP Receives FDA Clearance of its Ablatherm-Fusion Device
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
October 6, 2017
EDAP TMS received FDA approval of its Ablatherm-Fusion device that enables more precise targeting of diagnosed areas within the prostate.
The device combines MRI, 3D biopsy maps and ultrasound images to facilitate the targeting of areas to be ablated.
These new features improve Ablatherm's ability to perform efficient focal ablation of prostate tissue.
Upcoming Events
-
21Oct